Our study, for the first time, suggests the miR-22/IPO7/HIF-1α axis as new molecular target of curcumin, revealing innovative therapeutic implications of this natural compound for treatment of CML as well as of other cancer types in which HIF-1α has a prominent role. This evidence concerns the gene IPO7 and chronic myelogenous leukemia, BCR-ABL1 positive.